Journal article icon

Journal article

CpG-free plasmid expression cassettes for cystic fibrosis gene therapy.

Abstract:
Clinical studies are underway for the aerosol delivery of plasmid DNA complexed with Genzyme Lipid GL67A to the lungs of patients with cystic fibrosis (CF). Plasmid vectors contain several functional elements all of which play a role in determining the efficacy of the final clinical product. To optimise the final plasmid, variations of CpG-free 5' enhancer elements and 3'UTR regions were inserted into a common CpG-free, plasmid backbone containing Luciferase or CFTR transgenes. Plasmids were compared in immortalised cell culture, human airway liquid interface primary cell cultures, and mouse lung models to determine which design directed optimal transgene expression. Following aerosol delivery to mouse lung, plasmids containing the murine CMV enhancer showed higher peak Luciferase activity than the human CMV enhancer, but the human version resulted in persistent expression. In cell culture, the SV40 3'UTR and a novel BGH2 3'UTR exhibited up to 20-fold higher Luciferase activity than the commonly used BGH 3'UTR, but in mouse lung aerosol studies the activity and duration was greater for BGH 3'UTR. Systematic evaluation of each functional component of the plasmid has resulted in an improved design, exhibiting superior levels and duration of lung gene expression.
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1016/j.biomaterials.2012.06.009

Authors



Journal:
Biomaterials More from this journal
Volume:
33
Issue:
28
Pages:
6833-6842
Publication date:
2012-10-01
DOI:
EISSN:
1878-5905
ISSN:
0142-9612


Language:
English
Keywords:
Pubs id:
pubs:341240
UUID:
uuid:d915c697-34a1-48b4-a57a-538c697089e3
Local pid:
pubs:341240
Source identifiers:
341240
Deposit date:
2012-12-19

Terms of use



Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP